Skip to main content

CXR Biosciences, Wyeth Collaborate on $6.2M Drug Toxicity Marker Study

NEW YORK (GenomeWeb News) – The Scottish company CXR Biosciences said today it will work with the University of Dundee and Wyeth Pharmaceuticals in a £3 million ($6.2 million) collaboration to seek protein biomarkers that indicate the toxic effects of certain drugs.
CXR Bio said the three-year project is co-funded by the Technology Strategy Board and will be conducted in part by Wyeth scientists and by core lab staff at the Translational Medicine Research Center in Dundee.
The study intends to identify these markers and then develop assays to measure possible toxic effects of new drugs before they develop.
These assays then would be used in the lab to identify drug candidates that present too high of a risk to human safety to be advanced into clinical trials. They also could be used to give warnings of drugs that could lead to harm if the treatment is continued or if the dosing is increased, the company said. 
CXR Bio did not provide details about who will have ownership of intellectual property resulting from the collaboration.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.